CDIO 株価推移チャート
CDIO 財務
Cardio Diagnostics Holdings Inc
$2.01
-6.94%
$-0.15
終値： Aug 13, 16:00:00 GMT-4
$2.27
12.93%
$0.26
プレマーケット： Aug 14, 05:07:23 GMT-4
戻る
Cardio Diagnostics Holdings Inc (CDIO) 財務
収入
貸借対照表
現金の流れ
年次
四半期
CDIO 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Cardio Diagnostics Holdings Incの主要な財務諸表は何ですか？
CDIOの主要な財務比率は何ですか？
Cardio Diagnostics Holdings Incの収益はセグメントまたは地域別にどのように分けられていますか？
Cardio Diagnostics Holdings Incは収益を上げていますか？
Cardio Diagnostics Holdings Incに負債はありますか？
Cardio Diagnostics Holdings Incの発行済株式数は何株ですか？
主要データ
前終値
$2.16
始値
$2.28
当日レンジ
$2.01 - $2.33
52週レンジ
$0.97 - $7.91
取引高
182.7K
平均取引高
67.7K
配当利回り
--
1株当たり利益(TTM)
-3.38
時価総額
$6.7M
CDIOとは何ですか？
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 15 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
